
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc demonstrated a notable increase in its stock value during the third quarter, as the company advanced through four active Phase 3 trials with three lead assets, indicating strong progress in their pipeline and multiple anticipated data readouts through 2026. Research and development expenses rose significantly to $50.5 million, driven primarily by clinical and manufacturing costs, reflecting the company's commitment to furthering its innovative therapies. Encouraging follow-up data from the APEX study revealed continued improvement in best-corrected visual acuity (BCVA) for patients treated with KSI-101, adding to the positive outlook for Kodiak's product candidates and their potential market impact.
Bears say
Kodiak Sciences Inc faces significant challenges that contribute to a negative outlook on its stock, including the developmental candidates' potential failure to meet peak commercial revenue estimates due to market limitations and pricing issues. Additionally, the company has reported substantial financial losses, such as a net loss of $61.5 million in the third quarter of 2025, which raises concerns about its ability to secure the necessary capital for ongoing operations and commercialization efforts. Furthermore, the inconsistent efficacy of tarcocimab in clinical trials poses serious risks to the viability of its product pipeline and the overall success of its therapeutic platform.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares